Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Abbott Laboratories(NYSE:ABT), Arena Pharmaceuticals Inc.(NASDAQ:ARNA), MannKind Corporation(NASDAQ:MNKD), CEL-SCI Corporation(NYSEMKT:CVM)
Abbott Laboratories(NYSE:ABT) managed to keep its fall at -0.14% on above-normal volume of 7.92 million shares. The stock settled at $35.29 after floating in a range of $35.21 to $35.47. Its latest price was $35.29, reaching market capitalization of $54.85 billion. Its 52-week range has been $31.64 to $72.47. Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, pain, fever, inflammation, hypothyroidism, gynecological disorders.
Has ABT Found The Bottom and Ready To Move Up? Find Out Here
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) traded up on a volume of 8.26 million, higher than its standard daily volume. Shares have gained 2.42% to $5.93. Over the last twelve months, the stock has lost -34.83% and faced a worst price of $5.72. Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
For How Long ARNA will Fight for Profitability? Read This Trend Analysis report
MannKind Corporation(NASDAQ:MNKD) settled -0.34% lower at $5.93 on below-normal volume of 7.67 million shares during the last trading day. The stock has its 12-month high at $8.70 and 52-week low price was $1.82. It traded in a range of $5.85to $8.70 during the last trading day. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
Why Should Investors Buy MNKD After the Recent Fall ? Just Go Here and Find Out
CEL-SCI Corporation(NYSEMKT:CVM) saw its price fall on above-normal volume, as 6.54million shares changed hands when compared with its average daily volume of 1 586,497.00 shares. The stock was down -10.26% to $0.175. It has fallen over the last 12 months, dropping -51.93% and marked new low $0.16. CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company?s principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer.
Will CVM Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)